ATE475430T1 - Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls - Google Patents
Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) molekülsInfo
- Publication number
- ATE475430T1 ATE475430T1 AT04782353T AT04782353T ATE475430T1 AT E475430 T1 ATE475430 T1 AT E475430T1 AT 04782353 T AT04782353 T AT 04782353T AT 04782353 T AT04782353 T AT 04782353T AT E475430 T1 ATE475430 T1 AT E475430T1
- Authority
- AT
- Austria
- Prior art keywords
- boris
- brother
- regulator
- molecule
- cancer vaccine
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Inert Electrodes (AREA)
- Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
- Battery Electrode And Active Subsutance (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49751103P | 2003-08-25 | 2003-08-25 | |
| PCT/US2004/027856 WO2005021029A2 (en) | 2003-08-25 | 2004-08-25 | Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE475430T1 true ATE475430T1 (de) | 2010-08-15 |
Family
ID=34272574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04782353T ATE475430T1 (de) | 2003-08-25 | 2004-08-25 | Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7579452B2 (de) |
| EP (1) | EP1667711B1 (de) |
| JP (1) | JP2007504154A (de) |
| CN (1) | CN1871025B (de) |
| AT (1) | ATE475430T1 (de) |
| AU (1) | AU2004268001B2 (de) |
| CA (1) | CA2537161C (de) |
| DE (1) | DE602004028381D1 (de) |
| DK (1) | DK1667711T3 (de) |
| IL (1) | IL173943A (de) |
| RU (2) | RU2385163C2 (de) |
| WO (1) | WO2005021029A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005014659D1 (de) | 2004-09-21 | 2009-07-09 | Us Gov Health & Human Serv | Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs |
| US20090081245A1 (en) * | 2007-09-07 | 2009-03-26 | Reznik Boris N | Assays for development of boris mutants suitable for vaccine development and small molecule inhibitors of wild-type boris |
| EP2376089B1 (de) | 2008-11-17 | 2018-03-14 | The Regents of the University of Michigan | Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür |
| RU2666141C2 (ru) | 2013-09-17 | 2018-09-06 | Оби Фарма, Инк. | Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака |
| CN107148469B (zh) * | 2014-09-24 | 2021-06-25 | 北海道公立大学法人札幌医科大学 | 肿瘤抗原肽 |
| US11130798B2 (en) | 2015-05-19 | 2021-09-28 | La Jolla Institute For Allergy And Immunology | Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis |
| JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US11041017B2 (en) | 2016-03-29 | 2021-06-22 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20250048399A (ko) | 2016-04-22 | 2025-04-08 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
| WO2018022933A1 (en) | 2016-07-27 | 2018-02-01 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| EP3491026A4 (de) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren |
| JP2019535731A (ja) | 2016-11-21 | 2019-12-12 | オービーアイ ファーマ，インコーポレイテッド | コンジュゲートさせた生物学的分子、医薬組成物及び方法 |
| CN111479585A (zh) * | 2017-12-13 | 2020-07-31 | 艾诺奥医药品有限公司 | 靶向boris的癌症疫苗和其用途 |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU1438240C (ru) * | 1987-04-22 | 1996-03-20 | Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК РТNF 22, СОДЕРЖАЩАЯ ПОЛУСИНТЕТИЧЕСКИЙ ГЕН ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА - ПРОМЕЖУТОЧНАЯ ПЛАЗМИДА ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 31, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА |
| US5156841A (en) * | 1988-08-26 | 1992-10-20 | United States Of America | Anti-tumor vaccine |
| US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
| CN1326974A (zh) * | 2000-06-07 | 2001-12-19 | 上海博德基因开发有限公司 | 一种新的多肽——人转录阻抑蛋白ccctc－结合因子(ctcf)10.23和编码这种多肽的多核苷酸 |
| US20020141977A1 (en) * | 2001-04-02 | 2002-10-03 | Collins John Kevin | Immunotherapy based on dendritic cells |
| EP1573035B1 (de) * | 2002-02-22 | 2015-09-02 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Bruder des regulators geprägter stellen (boris) |
-
2004
- 2004-08-25 EP EP04782353A patent/EP1667711B1/de not_active Expired - Lifetime
- 2004-08-25 JP JP2006524877A patent/JP2007504154A/ja active Pending
- 2004-08-25 CN CN2004800314130A patent/CN1871025B/zh not_active Expired - Fee Related
- 2004-08-25 AT AT04782353T patent/ATE475430T1/de active
- 2004-08-25 RU RU2006109359/13A patent/RU2385163C2/ru active
- 2004-08-25 DE DE602004028381T patent/DE602004028381D1/de not_active Expired - Lifetime
- 2004-08-25 US US10/569,907 patent/US7579452B2/en not_active Expired - Lifetime
- 2004-08-25 DK DK04782353.9T patent/DK1667711T3/da active
- 2004-08-25 AU AU2004268001A patent/AU2004268001B2/en not_active Ceased
- 2004-08-25 WO PCT/US2004/027856 patent/WO2005021029A2/en not_active Ceased
- 2004-08-25 RU RU2010110441/10A patent/RU2556128C2/ru active
- 2004-08-25 CA CA2537161A patent/CA2537161C/en not_active Expired - Fee Related
-
2006
- 2006-02-26 IL IL173943A patent/IL173943A/en active IP Right Grant
-
2009
- 2009-08-24 US US12/546,561 patent/US8114405B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010110441A (ru) | 2011-09-27 |
| CA2537161C (en) | 2014-07-29 |
| WO2005021029A2 (en) | 2005-03-10 |
| DE602004028381D1 (en) | 2010-09-09 |
| US8114405B2 (en) | 2012-02-14 |
| EP1667711A2 (de) | 2006-06-14 |
| US7579452B2 (en) | 2009-08-25 |
| IL173943A (en) | 2011-04-28 |
| US20100166790A1 (en) | 2010-07-01 |
| US20060286115A1 (en) | 2006-12-21 |
| JP2007504154A (ja) | 2007-03-01 |
| EP1667711B1 (de) | 2010-07-28 |
| RU2006109359A (ru) | 2007-10-10 |
| CN1871025B (zh) | 2013-06-05 |
| CN1871025A (zh) | 2006-11-29 |
| AU2004268001B2 (en) | 2010-04-22 |
| AU2004268001A1 (en) | 2005-03-10 |
| DK1667711T3 (da) | 2010-11-22 |
| WO2005021029A3 (en) | 2005-05-26 |
| RU2556128C2 (ru) | 2015-07-10 |
| RU2385163C2 (ru) | 2010-03-27 |
| IL173943A0 (en) | 2006-07-05 |
| CA2537161A1 (en) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1667711T3 (da) | Forebyggende cancervaccine baseret på BORIS (Brother of Regulator of Imprinted Sites)-molekyle | |
| DE60232870D1 (de) | Neue polynukleotide und polypeptide des erythropoietingens | |
| ATE311457T1 (de) | Basb029 polynucleotide und polypeptide aus neisseria meningitis | |
| ATE333520T1 (de) | Neuartige polynukleotide und polypeptide des ifnalpha-21 gens | |
| DE60213402D1 (de) | Neue polynukleotide und polypeptide des ifn alpha-17-gens | |
| DE69941433D1 (de) | Von protease typ ii spaltbares peptid | |
| DK1186672T3 (da) | Polymorfismer i det humane gen for organiskaniontransporter C (OATP-C) | |
| GB0228832D0 (en) | Organic compound | |
| CY1108280T1 (el) | Basb205 πολυπεπτιδια και πολυνουκλεοτιδια που τα κωδικοποιουν | |
| DK1112366T3 (da) | Polynucleotider og polypeptider BASB033 fra Neisseria Meningitidis samt deres anvendelser | |
| WO2003093305A3 (en) | Teneurin c-terminal associated peptides (tcap) and uses thereof | |
| ATE449107T1 (de) | Aus fisch gewonnene peptide und nukleinsäuren der cathelicidin familie und deren verwendung | |
| WO2003006671A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| ATE328082T1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| ATE281524T1 (de) | Moraxella catarrhalis pilq proteine | |
| ATE498012T1 (de) | Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon | |
| ATE443715T1 (de) | Polypeptide aus haemophilus influenza | |
| DE60320835D1 (de) | Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür | |
| WO2002072765A3 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2002077190A8 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2002077193A8 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2002068648A3 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these humans ras-like proteins, and uses thereof | |
| ATE515511T1 (de) | Nicht-typisierbare haemophilus influenzae basb201 polypeptide und polynukleotide und deren verwendungen | |
| WO2002061088A3 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2002074976A3 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1667711 Country of ref document: EP |